Stock listing
SIX Swiss:BIOV BioVersys AG Aktie
Home listing (SIX Swiss) of BioVersys AG
Follow BioVersys AG into a list and get an email when it puts out news.
Share price · SIX:BIOV
22.10 CHF -1.80 (-7.5%)
Close on Nov 20, 2026
- Day range
- 22.10 – 23.90 CHFNov 20, 2026
- Volume
- 9,078 sharesNov 20, 2026
- Market cap
- 129.4M CHFAt the close on Nov 20, 2026 · price × 5.85M shares outstanding
- 52-week range
- 21.20 – 30.70 CHFLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 66,648 CHFMedian day 2,309 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss:BIOV · Home | 22.10 CHF | -1.80 (-7.5%) | 9,078 | 23.50 | 23.90 | 22.10 | 23.90 | Close on Nov 20, 2026 |
| Frankfurt:W33 | €24.40 EUR | -0.20 (-0.8%) | — | €24.60 | €25.00 | €24.40 | €24.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SIX:BIOV · CHF, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 22.10 | -1.80 | -7.5% | 23.50 | 23.90 | 22.10 | 9,078 | |
| 23.90 | +0.90 | +3.9% | 23.00 | 23.90 | 22.50 | 14,328 | |
| 23.00 | 0.00 | 0.0% | 22.90 | 23.00 | 22.60 | 1,017 | |
| 23.00 | -0.40 | -1.7% | 22.80 | 23.10 | 22.40 | 3,203 | |
| 23.40 | -0.50 | -2.1% | 23.70 | 23.70 | 23.40 | 594 | |
| 23.90 | +1.30 | +5.8% | 23.00 | 23.90 | 22.40 | 681 | |
| 22.60 | -0.90 | -3.8% | 23.60 | 23.60 | 22.50 | 1,224 | |
| 23.50 | +1.00 | +4.4% | 22.70 | 23.50 | 22.70 | 3,552 | |
| 22.50 | +0.10 | +0.4% | 22.20 | 22.50 | 22.00 | 4,014 | |
| 22.40 | 0.00 | 0.0% | 23.00 | 23.00 | 22.40 | 2,858 | |
| 22.40 | -0.20 | -0.9% | 22.50 | 23.00 | 22.30 | 5,306 | |
| 22.60 | -0.20 | -0.9% | 23.20 | 23.20 | 22.40 | 2,372 | |
| 22.80 | +0.30 | +1.3% | 23.60 | 23.60 | 22.50 | 2,371 | |
| 22.50 | -0.70 | -3.0% | 23.60 | 23.60 | 22.50 | 3,047 | |
| 23.20 | -0.30 | -1.3% | 23.20 | 24.80 | 23.20 | 4,041 | |
| 23.50 | +0.10 | +0.4% | 23.40 | 24.90 | 23.20 | 2,978 | |
| 23.40 | -0.20 | -0.8% | 24.30 | 24.40 | 23.40 | 1,576 | |
| 23.60 | -0.90 | -3.7% | 23.60 | 23.90 | 23.40 | 2,252 | |
| 24.50 | -0.20 | -0.8% | 23.40 | 24.70 | 23.40 | 3,310 | |
| 24.70 | +1.40 | +6.0% | 24.70 | 24.70 | 23.40 | 2,228 | |
| 23.30 | -1.50 | -6.0% | 24.80 | 24.80 | 23.30 | 5,974 | |
| 24.80 | +0.40 | +1.6% | 24.80 | 24.80 | 24.30 | 948 | |
| 24.40 | -0.40 | -1.6% | 24.80 | 24.80 | 24.40 | 475 | |
| 24.80 | -0.60 | -2.4% | 24.70 | 24.80 | 24.20 | 1,623 | |
| 25.40 | -0.50 | -1.9% | 25.90 | 25.90 | 24.90 | 1,464 | |
| 25.90 | 0.00 | 0.0% | 25.80 | 25.90 | 25.40 | 1,166 | |
| 25.90 | +0.80 | +3.2% | 24.70 | 25.90 | 24.50 | 2,302 | |
| 25.10 | -0.30 | -1.2% | 25.10 | 25.50 | 24.80 | 4,090 | |
| 25.40 | -1.10 | -4.2% | 25.10 | 26.40 | 25.10 | 5,397 | |
| 26.50 | 0.00 | 0.0% | 25.70 | 26.50 | 25.70 | 301 | |
| 26.50 | -0.30 | -1.1% | 26.80 | 26.80 | 26.40 | 289 | |
| 26.80 | +0.80 | +3.1% | 25.60 | 26.90 | 25.60 | 312 | |
| 26.00 | -0.90 | -3.3% | 25.60 | 26.50 | 25.60 | 1,404 | |
| 26.90 | -0.10 | -0.4% | 27.00 | 27.00 | 25.50 | 392 | |
| 27.00 | -0.20 | -0.7% | 27.40 | 27.40 | 27.00 | 1,245 | |
| 27.20 | -0.20 | -0.7% | 25.50 | 27.40 | 25.50 | 257 | |
| 27.40 | +0.90 | +3.4% | 26.80 | 27.40 | 25.30 | 360 | |
| 26.50 | +0.50 | +1.9% | 26.00 | 26.50 | 25.10 | 994 | |
| 26.00 | -0.20 | -0.8% | 25.70 | 26.00 | 25.40 | 151 | |
| 26.20 | +0.80 | +3.1% | 27.30 | 27.30 | 26.00 | 2,139 | |
| 25.40 | +0.10 | +0.4% | 25.30 | 25.80 | 25.00 | 2,671 | |
| 25.30 | -1.20 | -4.5% | 26.70 | 26.80 | 25.30 | 3,400 | |
| 26.50 | -0.10 | -0.4% | 26.60 | 28.40 | 26.50 | 2,432 | |
| 26.60 | -2.00 | -7.0% | 28.40 | 28.40 | 26.60 | 3,466 | |
| 28.60 | +0.50 | +1.8% | 28.00 | 28.60 | 28.00 | 4,074 | |
| 28.10 | +1.10 | +4.1% | 27.00 | 28.10 | 26.90 | 449 | |
| 27.00 | -1.20 | -4.3% | 28.10 | 28.10 | 27.00 | 2,798 | |
| 28.20 | +1.20 | +4.4% | 28.40 | 28.40 | 27.00 | 2,071 | |
| 27.00 | -0.20 | -0.7% | 27.40 | 27.40 | 26.50 | 4,489 | |
| 27.20 | +0.70 | +2.6% | 26.90 | 27.20 | 26.60 | 3,141 | |
| 26.50 | -0.90 | -3.3% | 27.00 | 27.00 | 26.50 | 4,103 | |
| 27.40 | -1.10 | -3.9% | 28.50 | 28.50 | 26.80 | 2,315 | |
| 28.50 | +0.50 | +1.8% | 28.00 | 28.50 | 28.00 | 1,398 | |
| 28.00 | 0.00 | 0.0% | 28.20 | 28.50 | 28.00 | 3,206 | |
| 28.00 | +0.10 | +0.4% | 27.90 | 28.00 | 27.30 | 1,972 | |
| 27.90 | -0.30 | -1.1% | 28.00 | 28.00 | 26.50 | 4,711 | |
| 28.20 | +3.30 | +13.3% | 26.80 | 28.50 | 26.80 | 12,773 | |
| 24.90 | +0.10 | +0.4% | 26.00 | 26.00 | 24.50 | 842 | |
| 24.80 | -2.00 | -7.5% | 26.00 | 26.00 | 24.80 | 1,167 | |
| 26.80 | +2.10 | +8.5% | 25.80 | 26.80 | 25.40 | 2,359 | |
| 24.70 | -0.60 | -2.4% | 25.40 | 25.40 | 24.30 | 2,517 | |
| 25.30 | +0.10 | +0.4% | 25.10 | 25.30 | 24.80 | 430 | |
| 25.20 | +0.40 | +1.6% | 25.00 | 25.40 | 25.00 | 2,478 | |
| 24.80 | 0.00 | 0.0% | 25.00 | 25.30 | 24.80 | 311 | |
| 24.80 | -0.40 | -1.6% | 25.00 | 25.00 | 24.80 | 1,152 | |
| 25.20 | +0.10 | +0.4% | 25.00 | 25.60 | 25.00 | 2,983 |
- Ticker
- SIX Swiss:BIOV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- SIX Swiss
- Currency
- CHF
What changed lately
Latest news release · Sep 9, 2026
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
Latest deck · Sep 9, 2026
Q3 2026 Earnings Presentation
Earnings · 46 slides
Latest news
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
Sep 9, 2026
Closed 27.40 (-3.9%) on Sep 9, 2026
BioVersys to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 3, 2026
Closed 28.00 (+0.4%) on Sep 4, 2026
BioVersys granted Fast-Track Designation from US FDA for BV100
Sep 2, 2026
Closed 28.20 (+13.3%) on Sep 2, 2026
BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call
Aug 26, 2026
Closed 25.30 (+0.4%) on Aug 26, 2026
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Apr 30, 2026
Closed 27.50 (-3.2%) on May 4, 2026
BioVersys completes BV100 Phase 1 clinical trial in China
Apr 22, 2026
Closed 29.00 (-3.0%) on Apr 22, 2026
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
Apr 16, 2026
Closed 29.50 (+1.7%) on Apr 16, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
Apr 15, 2026
Closed 29.00 (+3.6%) on Apr 15, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
Apr 13, 2026
Closed 27.00 (+1.9%) on Apr 13, 2026
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders
Apr 7, 2026
Closed 26.50 (-10.5%) on Apr 7, 2026
BioVersys AG on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 24 in all · newest Sep 9, 2026 · oldest 2025
- Decks
- 3 decks · latest Sep 9, 2026
Where BioVersys AG is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| SIX Swiss:BIOV · Home listing · This page | SIX Swiss | Switzerland | CHF |
| Frankfurt:W33 | Frankfurt | Germany | EUR |
| Turquoise:BIOVZ | Turquoise | United Kingdom | CHF |
Valuation
EV/sales 102× against a median of 45.5×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 81.82M CHF
- P/E
- Loss
- EV/sales
- 102×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.9×
- Gross margin
- −386.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioVersys AG · SIX:BIOV | US$154.1M | US$97.45M | n/a | 102× | n/a | 2.9× | n/a | 0.5× | n/a |
| TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157 | US$161.1M | US$133.4M | 34.2× | 17.1× | 46.8× | 5.2× | 60.5% | 0.0× | n/a |
| ImmuneOncia Therapeutics Inc. · KRX:424870 | US$160.0M | US$90.35M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Baijin Life Science Holdings Limited · HKEX:1466 | US$160.0M | US$158.1M | n/a | 13.9× | n/a | 6.8× | −42.4% | 0.1× | n/a |
| Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179 | US$157.3M | US$230.0M | n/a | 124× | n/a | 2.1× | n/a | 1.4× | n/a |
| InflaRx N.V. · NASDAQ:IFRX | US$153.3M | US$135.7M | n/a | 4,215× | n/a | 19.5× | n/a | 0.0× | 1.61 |
| Polaris Group · TWSE:6550 | US$153.0M | US$154.8M | n/a | 75.1× | n/a | 1.1× | n/a | 0.5× | n/a |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Median of the others | US$153.1M | US$118.7M | 21.3× | 45.5× | 26.0× | 2.5× | 0.4% | 0.0× | 1.61 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 65.80 CHF · Analysts' mean
- EPS, year to Dec 2026
- -5.81 · 6 analysts
- Revenue, year to Dec 2026
- 3.22M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Gitzinger | Chief Executive Officer & Founder |
| Hernan Levett | Chief Financial Officer |
| Anca Cighi | Head of Investor Relations and Communications |
| Alexander Lederer | Head of Intellectual Property |
| Daniel Ritz | Chief Scientific Officer |
| Fiona Gao | Head of Legal |
| Glenn Dale | Chief Development Officer |
| Jonathan James Butcher | Head of Business Development & Alliance Management |
Board
| Director | Role |
|---|---|
| Seng Chin Mah | Chairman |
| David Hunstad | Board Member |
| Marc Gitzinger | Chief Executive Officer & Founder |
| Marina von Schönau | Board Member |
| Simona Skerjanec | Board Member |
| Ulrik Schulze | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 1, 2026 | +3.5% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | +7.7% |
| Q2 2025 | Sep 10, 2025 | −3.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 46 slides | Sep 9, 2026 |
| H1 2026 Earnings Presentation | Earnings | 21 slides | Sep 9, 2026 |
| FY2025 Earnings Presentation | Earnings | 27 slides | Mar 18, 2026 |
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 800.0K | 0 |
| Cost of revenue | 3.89M | 3.95M |
| Gross profit | -3.09M | -3.95M |
| Research and development | 16.5M | 12.9M |
| Operating income | -20.0M | -18.7M |
| Depreciation and amortization | 297.0K | 282.0K |
| EBITDA | -19.7M | -18.4M |
| Interest expense | 1.08M | 1.04M |
| Income before tax | -21.8M | -18.7M |
| Net income | -21.8M | -18.7M |
| Earnings per share, basic | -3.73 | -3.16 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 82.5M | 26.6M |
| Short-term investments | 6.00M | |
| Current assets | 89.9M | 34.4M |
| Total assets | 90.6M | 35.0M |
| Accounts payable | 2.47M | 706.0K |
| Current liabilities | 8.90M | 9.67M |
| Long-term debt | 21.3M | 13.6M |
| Total liabilities | 30.8M | 24.3M |
| Shareholders' equity | 59.8M | 10.7M |
| Shares outstanding | 5.85M | 5.91M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -21.9M | -15.6M |
| Capital spending | -216.0K | -38.0K |
| Free cash flow | -22.2M | -15.6M |
| Change in cash | 56.4M | 1.58M |
Cap table
Built by 6ix from BioVersys AG’s releases
- Common shares
- 5,854,584
- Fully diluted
- 5,854,584
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,854,584 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,854,584 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexander Lederer | Head of Intellectual Property · Since at least Nov 5, 2026 |
| Anca Cighi | Head of Investor Relations and Communications · Since at least Apr 2, 2026 |
| Daniel Ritz | Chief Scientific Officer · Since at least Mar 31, 2026 |
| David Hunstad | Board Member · Since at least Apr 30, 2026 |
| Fiona Gao | Head of Legal · Since at least Nov 5, 2026 |
| Glenn Dale | Chief Development Officer · Since at least Apr 22, 2026 |
| Hernan Levett | Chief Financial Officer · Since at least Sep 9, 2026 |
| Jonathan James Butcher | Head of Business Development & Alliance Management · Since at least Nov 4, 2026 |
| Marc Gitzinger | Chief Executive Officer & Founder · Since at least Sep 9, 2026 |
| Marina von Schönau | Board Member · Since at least Apr 30, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Seng Chin Mah | Chairman · Since at least Apr 30, 2026 |
| Simona Skerjanec | Board Member · Since at least Apr 30, 2026 |
| Ulrik Schulze | Board Member · Since at least Apr 30, 2026 |
Log in to ask 6ix AI your own questions about BioVersys AG.